OB/GYN Clinical Alert articles from December 2004

OB/GYN Clinical Alert archives from December 2004

Obstetrical prognosis after placental abruption.(Abstract & Commentary)
December 1, 2004... IN A RECENT STUDY FROM JAPAN, TOIVONEN AND COLLEAGUES set out to determine how much more susceptible women experiencing placental abruption were to having a recurrence of this problem in a subsequent pregnancy. They scanned a database which...

Venous thrombosis and type of treatment.(Abstract & Commentary)
December 1, 2004... Synopsis: A case-control study suggests that the risk of venous thrombosis differs according to the type of estrogen used. Source: Smith NL, et al. JAMA. 2004;292:1581-1587. SMITH AND COLLEAGUES PERFORMED A CASE-CONTROL study of venous...

Usefulness of history, physical, and laboratory in evaluating vaginal complaints.(Abstract & Commentary)
December 1, 2004... Synopsis: In working up vaginitis symptoms, useful signs are inflammation and odor, information concerning odor and itching are useful symptoms, and office microscopy is the most accurate laboratory test. Source: Anderson MR, et al. JAMA....

Aromatase inhibitor for severe endometriosis.(Abstract & Commentary)
December 1, 2004... Synopsis: Successful treatment of severe endometriosis in 2 premenopausal patients is reported. Source: Shippen ER, West WJ. Fertil Steril. 2004;81: 1395-1398. Two PREMENOPAUSAL PATIENTS WITH RESISTANT endometriosis were successfully...

Timing isn't everything, right?(Abstract & Commentary)
December 1, 2004... Synopsis: Nearly 70% of patients achieving a CR after primary therapy eventually recurred. Most recurrences occurred more than 6 months from completion of primary chemotherapy, and the use of second line agents at the time of recurrence was...

Postmenopausal hormone therapy and venous thrombosis.(Abstract & Commentary)
December 1, 2004... Synopsis: Postmenopausal hormone therapy increases the risk of venous thrombosis, especially in overweight, older women. Source: Cushman M, et al. JAMA. 2004;292: 1573-1580. RESULTS FROM THE ESTROGEN-PROGESTIN ARM OF the Women's Health...

CME question.
December 1, 2004... 10 The following statements are true regarding postmenopausal hormone therapy and the risk of venous thrombosis except: a. It is possible to designate those women who are at higher risk. b. Statins or low dose aspirin treatment prevent...

ACE inhibitors and receptor blockers: which is inferior?
December 1, 2004... The first head-to-head comparison study of an CE inhibitor and an angiotensin receptor blocker, to assess renoprotective effects in type 2 diabetes, has shown that the drugs are comparable in their benefit. It has been known for more than a...

The infection risk of acid-suppressing drugs.(Brief Article)
December 1, 2004... Ever since cimetadine was first marketed in 1977, physicians have been concerned about the risk of infection associated with acid-suppressing drugs. Now researchers from the Netherlands have shown that concern is warranted, by demonstrating a...

Is rosuvastatin as safe as other statins?(Brief Article)
December 1, 2004... Rosuvastatin (Crestor), AstraZeneca's entry into the high potency statin market, has not achieved marketshare comparable to Pfizer's atorvastatin (Lipitor) or Merck's simvastatin (Zocor). This, despite the facts that the drug is very potent and...

Which estrogen preparation is the safest?
December 1, 2004... Is esterified estrogen safer than conjugated equine estrogen? At least with regard to venous thrombosis, the answer may be yes, according to a recent study. Group Health Cooperative in Washington State, a large HMO, switched their patients from...

FDA actions.(Brief Article)
December 1, 2004... Serono has been given approval to market recombinant human luteinizing hormone (Luveris) for the treatment of infertility in women. The drug, which was granted orphan status, has been available in more than 60 countries for several years. ...

Toenail chromium in men with diabetes and cardiovascular disease.(Brief Article)
December 1, 2004... Source: Rajpathak M, et al. Diabetes Care. 2004;27(9):2211-2216. AT ONE TIME IN THE NUTRITION LITERATURE, known as glucose tolerance factor. The role of CRM in glucose homeostasis was further corroborated by studies of Asians with diets...

Combination of fenofibrate and rosiglitazone and HDL cholesterol.(Brief Article)
December 1, 2004... Source: Normen L, et al. Diabetes Care. 2004;27(9):2241-2242. THE PRIMARY FOCUS OF LIPID CONTROL, even amongst diabetics, I remains the LDL level, since most accumulated data provides good support for improvement in cardiovascular outcomes...

Outcomes for patients with diet-controlled diabetes.(Brief Article)
December 1, 2004... Source: Hippisley-Cox J, Pringle M. Lancet. 2004;363:423-428. THE UNITED KINGDOM PROSPECTIVE diabetes Study (UKPDS) is the I landmark clinical trial which forms the foundation for treatment of persons with type 2 diabetes (DM2). UKPDS...

Erythromycin and the risk of sudden death.(Brief Article)
December 1, 2004... Source: Ray W, et al. N Engl d Med. 2004;351:1089-1096. AGENTS WHICH ALTER CARDIAC repolarization have been associated with torsades de pointes. Although erythmmycin (ERY) is a generally safe and efficacious medication, it does have the...

Acute hyperglycemia, mood, and cognitive performance in type 2 diabetics.(Brief Article)
December 1, 2004... Source: Sommerfield AJ, et al. Diabetes Care. 2004;27(10):2335-2340. HYPERGLYCEMIA IN DIABETES IS ASSOCIATED with increased incidence of neuropathy, nephropathy, and retinopathy. Data about the effects of hyperglycemia upon cognitive...

Psychosocial risk factors and risk of acute MI.(myocardial infarction )(Brief Article)
December 1, 2004... Source: Rosengren A, et al. Lancet. 2004;364:953-962. STUDIES IN NORTH AMERICA, Europe and Japan have provided some support for the concept that emotional stress is a risk factor for coronary bean disease (CHD), but there is scanty...